The market for rheumatoid arthritis testing is expected to witness a compound annual growth rate (CAGR) of 2.4% despite cost-cutting on healthcare, lower reimbursement in major markets and sluggish growth in Europe, says a report by GlobalData.

Entitled ‘MediPoint: Rheumatoid Arthritis Testing – Global Analysis and Market Forecasts‘, the report covers 15 major markets and forecasts that the rheumatoid arthritis testing market will be valued at $399.5m by 2022, raising modestly from $338.5m in 2015.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Rising incidences of autoimmune diseases, emerging biomarkers and technology advancements resulting in early diagnosis of the disease are some factors that will contribute to the anticipated growth. Furthermore, commercialisation of anti-cyclic citrullinated peptide (anti-CCP) antibody tests and increasing demand for lab automation are expected to propel the growth.

“The report highlights cost-cutting and falling reimbursement will be barriers to growth.”

Anti-CCP tests are currently widely accepted and is the most attractive segment, which is expected to grow at a steady pace during the forecast period.

However, the report highlights cost-cutting and falling reimbursement will be barriers to growth. European nations such as Germany too also witness a sluggish growth of low single-digit CAGR during the period.

Emerging markets, especially Brazil, will offer faster growth to manufacturers, adds the report. Growing middle class and increasing investment in physical infrastructure are some of the reasons behind the anticipated growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche, Abbott, Siemens, and Beckman Coulter dominated the rheumatoid arthritis testing market in 2015, according to the report.